FORM PTO-1390 (Rev 10-9-94)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371

J.S. DEPARTMENT OF COMMIDIES

Patent and Trademark Office

Docket No 246472001600

09/646355

	U.S. APPLICATION NO. (I	If known, see 37 C.F.R. § 1.5):				
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
PCT/EP99/01374 / 3 March 1999 / 18 March 1998 /						
TITLE OF INVENTION:						
DRUG FOR THE PROPHYLAXIS AND/OR TREATMENT OF BREAST CANCER, COMPRISING A STEROIDAL						
AROMATASE INHIBITOR	TREATMENT OF BREAST CANCER, CC	JVII Iddii (O / O I E (O E I I E				
APPLICANT(S) FOR DO/EO/US: Alfred SO	PHMIDT et al					
Applicant herewith submits to the United Sta		he following items and other				
information:	tes Designated/Elected Office (DO/EO/OS) t	ne tonowing terms and outer				
	ns concerning a filing under 35 U.S.C. § 371.					
	ENT submission of items concerning a filing					
	nal examination procedures (35 U.S.C. § 371					
examination until the expiration of	the applicable time limit set in 35 U.S.C. § 3	71(b) and PCT Articles 22 and 39(1).				
4. 🗷 A proper Demand for International	Preliminary Examination was made by the 1	9th month from the earliest claimed				
priority date.						
	ation as filed (35 U.S.C. § 371(c)(2))					
	ed only if not transmitted by the International	Bureau).				
b. 🗷 has been transmitted by the Int		OCC (DOCTS)				
	on was filed in the United States Receiving C					
	pplication into English (35 U.S.C. § 371(c)(2					
	nternational Application under PCT Article 1					
	a. are transmitted herewith (required only if not transmitted by the International Bureau).					
b. have been transmitted by the International Bureau.						
c. \square have not been made; however, the time limit for making such amendments has NOT expired. d. \square have not been made and will not be made.						
		8 371(c)(3)).				
1	 8. □ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)). 9. □ An oath or declaration of the inventor(s) (35 U.S.C. § 371(c)(4)). 					
		rt under PCT Article 36				
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).						
Items 11. to 16. below concern document	(s) or information included:					
11. 🗷 An Information Disclosure Statem	ent under 37 C.F.R. §§ 1.97 and 1.98.					
	ding. A separate cover sheet in compliance v	with 37 C.F.R. §§ 3.28 and 3.31 is				
included.						
13. A FIRST preliminary amendment.						
☐ A SECOND or SUBSEQUENT pr	eliminary amendment.					
14. A substitute specification.						
15. ☐ A change of power of attorney and						
16. E Other items or information: 1. Va	rious PCT documents 2. Return receipt postc	ard.				
	CERTIFICATE OF HAND DELIVERY					
I hereby certify that this correspondence is being hand	filed with the United States Patent and Trademark Offic	ce in Washington, D.C. on September 18, 2000.				
1	Varieta Luke					
Januare Whetstone						

534 Rec'd PCT/PTO 18 SEP 2000

HS	APPLICATION NOTION of	Lsed 37/C.FR. FL.	INTERNATION	NAL	DOCKET	
0.0.	APPLICATION NO. 10 now	940233	APPLICATION	NO. PCT/EP99/01374	NUMBER: 2464	172001600
17.	■ The following fees	are submitted: FEE (37 C.F.R. §§ 1.492	(a)(1)-(5)):		CALCULATION USE ONLY	ONS PTO
	Neither international pr	reliminary examination for fee (37 CFR 1.445(a)(2) h Report not prepared by	ee (37 CFR 1.482))) paid to USPTO	\$840.00		
	International prelimina	ry examination fee (37 C al Search Report prepare	FR 1.482) not paid to			
	by international search	ry examination fee (37 C fee (37 CFR 1.445(a)(2)) paid to USPTO	\$690.00		
	but all claims did not s	ry examination fee paid tatisfy provision of PCT A	Article 33(1)-(4)	\$970.00		
	International prelimina and all claims satisfied	ry examination fee paid provisions of PCT Artic	le 33(1)-(4)	\$96.00	\$600.00 T	
				BASIC FEE AMOUNT =	\$690.00	
		For furnishing the oath or ority date (37 C.F.R. § 1	.492(e)).		\$0	*****
	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$0	
	Total claims	13 - 20 =	0	x \$18.00	\$0	
	Independent claims	1 - 3 =	0	x \$78.00	\$0	
	MULTIPLE DEPEND	ENT CLAIM(S) (if appl	icable)	+ \$260.00	\$260.00	
	1110211122	(-)(11		VE CALCULATIONS =	\$950.00	
	Reduction by ½ for file also be filed (Note 37)	ing by small entity, if app C.F.R. §§ 1.9, 1.27, 1.28	olicable. Verified Small	Entity Statement must	\$0	
				SUBTOTAL =	\$950.00	
	Processing fee of \$130 □ 20 □ 30 months from	0.00 for furnishing the Enom the earliest claimed p	glish translation later tha riority date (37 C.F.R. §	n 1.492(f)). +	\$0	
				TAL NATIONAL FEE =	\$950.00	
	Fee for recording the e	enclosed assignment (37 propriate cover sheet (37	C.F.R. § 1.21(h)). The a C.F.R. §§ 3.28, 3.31). §	ssignment must be 40.00 per property +	\$0	
			ТОТ	AL FEES ENCLOSED =	\$950.00	
					Amount to be refunded:	\$
					charged:	\$

- a. A check in the amount of \$950.00 to cover the above fees is enclosed.
- b. Example The Assistant Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to **Deposit Account No. 03-1952**.

NOTE: Where an appropriate time limit under 37 C.F.R. § 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Barry E. Bretschneider Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888

Barry E. Bretschneider Registration No. 28,055

09/646355 534 Rec'd PCT/PTO 18 SEP 2000

Docket No. 246472001600

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on September 18, 2000.

Marieta Luke
LaVerne Whetstone

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Alfred SCHMIDT et al.

Serial No.: Not yet Assigned

Filing Date: September 18, 2000

For: DRUG FOR THE PROPHYLAXIS

AND/OR TREATMENT OF BREAST

CANCER, COMPRISING A STEROIDAL AROMATASE

INHIBITOR

Examiner: Not yet Assigned

Group Art Unit: Not yet Assigned

PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to the calculation of the filing fee for this application, as part of this original application filing, please enter the following amendment:

IN THE SPECIFICATION

Page 9, line 14, change "hydrophilicity" to --hydrophobicity--.

REMARKS

The amendment to the specification above corrects an obvious error in the original German-language text of the international application as translated into English in the text filed with this application. Persons skilled in the art would recognize that this error is obvious from the discussion starting at page 4, line 21, of the application as filed herewith, which refers to the lipophilicity and hydrophobicity of the active compound used in accordance with this invention, which is, as can readily be gleaned from the specification as filed, the acetylated formestane referred to at page 9, lines 13-15.

Early action entering this amendment and allowing the claims in this application is solicited.

In the event that the transmittal letter is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: September 18, 2000

Respectfully submitted,

By:

Barry E. Bretschneider

Reg. No. 28,055

Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W.

Washington, D.C. 20006-1888

Telephone: (202) 887-1545

Facsimile: (202) 887-0763

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT or PATENTEE:

SERIAL OF PATENT NO .:

FILED OF ISSUED:

CROUP:

TITLE

SMALL ENTITY DECLARATION

[] FOR INDEPENDENT INVENTOR(5)

As a below-named inventor, I hereby declars that I am an independent inventor who (I) has not swigned, granted, conveyed, or licensed, and (2) is under no obligation under contract or law, to swign, grant, convey, or license, any rights in the invention, to any person who could not filtowise be classified as an independent inventor if that person had made the invention, or to any ouncern which would not qualify as a small business concern or a nonprofit organization, as defined in 37-CFR 1.9.

[X] FOR SMALL BUSINESS CONCERN

I hereby declare that S.W. Patentverwertungs GubH is a business concern which qualifies as a small business concern as defined in §1.9(d) - namely. (I) whose number of employees, including those of its affiliates, does not arread 500 persons and (2) which has not assigned, granted, conveyed, or licensed, and is under not obligation under contract or law to easign, grant, convey, or license, my rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a comprofit organization under this section; and that the exclusive rights to the invention have been conveyed to and remain with the shove-identified small business concern.

I further declare that all statements made herein of tay own knowledge are true and all statements made on information and belief are believed to be true and further, that these statements were made with the knowledge that wilfful. Islandaments and the libe, so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful, false statements may jeopardize the validity of the patent application or any parent issuing thereon.

Each of the undersigned heathy grant the firm of Morrison & Foerster, LLP 2000 Pennsylvania Avenue, N.W., Washington, D.C. 20006-1888

Small Entity Decimation any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for filing and acceptance of this Decimation.

INVENTOR(S)	SMALL BUSINESE-CONCERN:
Name: AFRES CHMIST Date: Name: HENRICH WIELLAND Date: NgV, 15.2000	Name: WATKNIVERW Title: Gh2H Date: Nov. 15. 2002
Name: Date:	Name Title: Dubs: 11-15-26
Name: Date:	•

6/6 'S : VEL Empfangszeit

16. Nov. 10:44H TION CHIAN TAKEN

7012 FOR7 'AON 151

MPRTS

09/646355

PCT/EP99/61374 WO 99/47143 S.W. Patentverwertungs GmbH

534 Rec'd PCT/PTC 18 SEP 2000

5

DRUG FOR THE PROPHYLAXIS AND/OR TREATMENT OF BREAST CANCER, COMPRISING A STEROIDAL AROMATASE INHIBITOR

10

The invention relates to a medicament for the prophylaxis (primary and secondary prophylaxis) and/or treatment of breast cancer.

Breast cancer is the most frequent malignant disease in women. In Germany, breast cancer makes up about 20% of all cases of cancer in women; the incidence at present is about 30,000 new cases of disease per annum. The adjuvant cancer therapy used today does lead to an increase in the survival rate; breast cancer screening and early surgical treatment can also lower the mortality by over 30%. However, since the number of new cases of disease is continuously increasing, the death rate measured over the total population remains the same or increases. Until now, it has barely been possible to affect the number of new cases, as too little is known about triggering factors.

In approximately half of all breast cancers, oestrogen and/or progesterone receptors are found in the cytoplasm. Breast cancers of this type need oestrogen for the proliferation of their cells. Oestrogens act by binding to specific intracellular (cytoplasmic) receptors of oestrogen-sensitive cells, into which they are passively introduced by diffusion from the plasma. The binding changes the configuration of the re-

30

ceptor protein. The receptor-hormone complex controls both the transcription and the expression of specific genes; the synthesis of growth-promoting and/or growth-inhibiting factors caused thereby finally has an effect on cell growth.

5

10

15

. -

Confluiden Confluide fine fi

177

H H H

11 18 45.18 11.10 11.10 By withdrawal of oestrogens, regression of oestrogendependent tumours can be achieved. In premenopausal women, the ovaries are the main source of oestrogens. Their surgical removal has therefore been carried out since 1896 with breast cancer in the advanced stage (metastasis formation) as a socalled surgical hormone therapy.

In post-menopausal women, the conversion of adrenal androgens, especially androstenedione and testosterone, to oestrone and oestradiol is the main source of oestrogen. The conversion to oestrogens takes place in the muscle and fatty tissue.

20 advanced stages of breast cancer have been treated with tamoxifen or its derivatives (in particular tamoxifen citrate).

Tamoxifen occupies the oestrogen receptors located in the cytoplasm of the cancer cells and thus causes competitive displacement of oestrogens. The complex formed from tamoxifen and the oestrogen receptor prevents the transcription and the expression of genes promoting cell growth, which otherwise is caused by a complex formed from oestrogens and the receptor.

In in-vitro experiments, it has been demonstrated that ta30 moxifen also has a growth-inhibiting and, under certain circumstances, even cytostatic effect on cell lines which have
no oestrogen receptors. Tamoxifen inhibits protein kinase C

- In particular after relatively long treatment, tamoxifen can act on cancer cells as well as oestrogens in a manner which is not known in greater detail and promotes their growth.

 Relatively long-lasting tamoxifen treatment can therefore lead, under certain circumstances, to tumour growth. It
- moreover leads to a risk which is increased by a factor of 3 to 5 of suffering from cancer of the endometrium. In view of the clinical benefits of tamoxifen therapy, this risk is accepted in breast cancer patients.
- The systemic treatment of breast cancers with aromatase inhibitors, in particular 4-hydroxyandrost-4-ene-3,17-dione (INN formestane) is further known. Aromatase is a complex enzyme system which catalyses the conversion of adrenal androgens to oestrone and oestradiol.

Formestane is a derivative of the physiological steroid hormone androstenedione and binds competitively to other substrates of aromatase. During catalysis, it damages the enzyme molecule irreversibly. Systemic treatment with formestane is likewise used as an antioestrogenic breast cancer therapy.

The invention is based on the object of creating a medicament of the type mentioned at the outset, which is suitable for treatment, and in particular also prophylaxis, of breast cancer.

The invention achieves this object by formulating a steroidal aromatase inhibitor to give a medicament intended for topical

The figure of the first first from the fluid from the first first from the first

20

25

30

1 1

application. The use of antigestagens as an additional constituent of the medicament is excluded in the context of the invention.

5 Some terms used in the context of the invention will first be explained.

According to the invention, steroidal aromatase inhibitors are used as substances inhibiting the formation of oestrogens. These inhibit oestrogen biosynthesis from the androgenic precursors, for example the enzymatic conversion of androstenedione to oestrone or of testosterone to oestradiol. Since the two synthesis steps mentioned are mediated by the enzyme system of the aromatase (converting enzyme), aromatase inhibitors are used in the context of the invention. Preferred inhibitors are those which bind to the aromatase and irreversibly damage this. After topical application, they penetrate through the skin and concentrate in the fatty tissue.

20

25

30

10

15

. .

Ľį.

the think often their West

(f.,...

igi

in is

The medicament according to the invention is intended for topical application. The medicament is applied locally to the skin, the preferably strongly lipophilic active compound is transdermally absorbed and thus brought locally to the intended site of action. The active compound concentrates in the periductal fatty tissue. In a long-term treatment, the fatty matter of the treated breast is markedly reduced. This reduction decreases the quantity of oestrogen-forming cells having oestrogen-forming competence. The lipophilicity and hydrophobicity of the active compound has the result that the active compound is exclusively concentrated locally in the fatty tissue and can display no systemic action. Oestrogens

are understood as meaning all female sex hormones having an action comparable, for example, to that of oestrone and oestradiol.

In the use of aromatase inhibitors known from the prior art, such as formestane, it is intended to transport these to the site of action via the blood circulation. High serum concentrations of the aromatase inhibitor are aimed at, which, in addition to the desired action in the tumour, can lead to systemic side effects. In view of the severity of the illness, such side effects are accepted in acute therapy in view of the success desired. However, this does not come into consideration in the case of a preventive treatment against a still unexisting or clearly detected disease.

15

20

According to the invention, however, it is intended to apply the medicament topically immediately on or in the vicinity of the intended site of action. Unlike the prior art, no transport via the blood circulation to the intended site of action is aimed at. According to the invention, the result achieved is an adequate local active compound level in the tissue at risk (in prophylaxis) or in the diseased tissue (in therapy) without a noticeable absorption of the active compound taking place in the blood circulation. The crux of the invention is thus not only in the topical application per se, but in the local topical application in such a way that the active compound concentrates immediately in the tissue at risk and/or diseased tissue, and not indirectly via the blood circulation.

30

25

If metastasizing carcinomas are also to be treated and/or prophylaxis is to be carried out against these, the medica-

10

H. H. H. H. Ham Ham Can Built of the Boy Built Bing II F. H. F. T. south world them and if it and then then the

ij.

ment according to the invention can be applied topically to the intended site of action in such an amount that a noticeable absorption in the blood circulation additionally takes place and a serum level thus builds up which also transports the active compound to metastases. In this use too, a local absorption on or in the vicinity of the intended site of action also primarily takes place.

The medicament can be used for the treatment of breast cancer. After surgical primary care and, if appropriate, appropriate adjuvant therapy, this treatment can replace and/or supplement the hitherto customary systemic antioestrogenic therapy.

An important advantage of the invention is the possibility of also using the medicament for breast cancer prophylaxis. A particularly advantageous possibility of employment is so-called secondary prophylaxis. In female patients in whom a breast cancer is already present, there is a particularly high risk of a further carcinoma in the contralateral breast. The contralateral breast can then be treated prophylactically with the medicament according to the invention. A secondary prophylactic treatment of the diseased breast to avoid local recurrences is likewise possible.

25

30

In the case of so-called high-risk women, primary prophylaxis can be performed. The selection criteria which can be used for such a high-risk group are, for example, the facts that at least one female relative of first degree on the mother's side is or has been suffering from breast cancer on one side before the 45th year of life or bilaterally, or that on the mother's side at least one female relative of first degree

10

. .

and an additional female relative are or have been suffering from breast cancer. Since the local application according to the invention virtually completely avoids possible systemic side effects of the active compound on account of its hydrophobicity, the indication for primary prophylaxis can be made relatively generously already in the presence of tissue having a comparatively low or average risk (for example histological finding Prechtel II or III). Prophylaxis can be started even if the conventional early diagnosis (palpation finding) is still negative, since this customary early diagnosis is inadequate and as a rule only detects a breast cancer when a systemic disease which is barely still curable is already present.

The medicament according to the invention is preferably applied locally and topically over a relatively long period of time (if needed up to lifelong) and application is carried out, for example, once or twice per day.

The active substances are selected from the group consisting of the (preferably lipid-soluble) steroidal aromatase inhibitors. On topical application, these lipid-soluble substances penetrate into the fatty tissue and locally prevent the de novo formation of oestrogens from the oestrogen precursors.

25

30

For example, steroidal aromatase inhibitors such as 4-hydroxyandrost-4-ene-3,17-dione (formestane), 6-methyleneandrostra-1,4-diene-3,17-dione (exemestane), 10 - (2-propynyl) = 17 - (2-propynyl) = 17

. .

8

The names_mentioned in brackets are the INNs (International nonproprietary names). For the terminology and structure of the substances mentioned, reference is likewise made to the "Rote Liste" and Römpp's chemical encylopaedia.

5

10

Until now, the substances mentioned have only been used for the systemic therapy of breast cancer. According to the invention, however, the active compound is brought to the intended site of application by local application. When using aromatase inhibitors, the invention achieves a reduction of the aromatase activity in the fatty tissue of the breast, i.e. exactly in the position in which a tumour can be formed or grow. On relatively long-term use, the fatty matter of the breast and thus the amount of possible risk tissue is reduced. Since breast cancers are frequently formed in upper breast quadrants of increased aromatase activity, particularly effective prophylaxis is possible there according to the invention.

20

25

The use according to the invention of aromatase inhibitors can be employed prophylactically or therapeutically even against those tumours of the breast which are themselves able to produce oestrogen or autocrine/paracrine stimulation. A lowering of the oestrogen concentration in the plasma barely has an effect on such tumours, but the reduction of the intratumoral aromatase concentration to be achieved according to the invention can affect such tumours on account of the use of cell-permeable inhibitors.

30

Since the active compounds administered according to the invention remain localized in the fatty tissue of the breast and display their intended action there on account of their

٠.

9

lipid solubility, the side effects induced by systemic application are eliminated. This reduction or exclusion of side effects allows significantly wider prophylactic use. The medicament according to the invention can be applied by patients themselves and frequent visits to the doctor for this purpose are not necessary.

A medicament formulated according to the invention preferably contains formestane.

10

15

20

25

30

5

Formestane derivatives such as, for example, acetylated formestane (for example 4-0-acetylandrost-4-ene-3,17-dione) are likewise preferably utilizable. The acetylation of the formestane increases its hydrophilicity and thus skin penetration significantly. Since the acetyl group is hydrolysed under the conditions prevailing in the subcutaneous region after passage through the skin, the actual active compound formestane is formed again in situ. When using such an acetylated formestane, a precursor of the actual active compound penetrating better through the skin is thus applied and the inventors have recognized that the actual active compound is formed in situ subcutaneously from this precursor.

As a rule, the active compounds used according to the invention are lipid-soluble and highly suitable for topical application. As already described above, the concentration in the fatty tissue of the breast avoids systemic side effects. To improve the skin penetration, substances known in the prior art which promote this can be added to the medicament according to the invention, for example hyaluronidases or DMSO (dimethyl sulphoxide).

٨,

The medicament is preferably formulated as an ointment, cream, gel, emulsion or lotion. Formulation as a powder or oil is also conceivable. Formulation bases are familiar to the person skilled in the art from the cosmetic and pharmaceutical industry and do not need to be explained here in greater detail. For example, vegetable oils and fats such as almond oil, peanut oil, olive oil, peach kernel oil, castor oil, plant extracts, ethereal oils; furthermore vegetable waxes and synthetic and animal oils, fats or waxes; lecithin, lanolin alcohols, carotene, fragrances, mono- or polyhydric alcohols, urea, preservatives and colourants etc. can be used. Formulation as an oil-in-water or water-in-oil emulsion is preferred.

15

10

5

The active compound content of the medicament (the content of substances inhibiting the formation of oestrogens) can be between 0.0001 and 20% by weight, preferably 0.6 and 10% by weight, further preferably 1 and 5% by weight. A customary range is 0.6 to 2% by weight.

20

If substances are admixed to promote skin penetration absorption, their content, when using hyaluronidases, can be, for example, between 0.01 and 1% by weight, preferably 0.05 and 0.2% by weight; when using DMSO between 1 and 25% by weight, preferably 5 and 10% by weight.

Embodiments of the invention are described below. In the drawing:

30

25

- Fig. 1 shows the cytological result of a fatty cell aspirate before use of the medicament according to the invention,
- 5 Fig. 2 shows the corresponding result after daily use over the course of 3 months.

Example 1

10 The following constituents were mixed to give a cream:

Urea	10	g
Titanium oxide	15	g
Crude petroleum jelly	20	g
Isopropyl palmitate	10	g
Hardened peanut oil	10	g
Tween 80	5	g
Formestane	1	g
made up with purified water to	100	g

Example 2

15 A gel was prepared from the following constituents:

Ethanol 90%	7.0 g
Carbopol [®] 934 P	7.0 g
Triethanolamine	2 g
Polysorbate 80	5.0 g
Glycerol	3.0 g
Formestane	0.75 g
purified water to	100 g

12

Example 3

A cream was prepared from the following constituents:

Propylene glycol	25.0	g
Isopropyl myristate	6.0	g
Sorbitan monostearate	1.0	g
Polysorbate 80	2.0	g
Cetylstearyl alcohol	6.0	g
Stearyl alcohol	2.0	g
Glycerol monostearate	1.0	g
Hyaluronic acid	0.1	g
Formestane	1.5	g
purified water to	100	g

Example 4

A cream was prepared from the following constituents. The constituents are indicated in this example by their INCI names.

┰	7.7	^	~
т	T.A	C	1

Ceteareth-25	3.0 g
PEG-4-polyglyceryl 2-stearate	2.0 g
Cetearyl alcohol	4.9 g
Petrolatum	10.0 g
Paraffinum perliquidum	3.0 g
Sodium carbomer 400	0.14 g
Lactic acid	0.02 g
Paraffinum perliquidum	2.0 g

Phenoxyethanol, dehydroacetic acid, ben-

zoic acid	0.4	g
Perfume	0.08	g
Formestane	1.5	g
made up with water to	100	g

The mixture of phenoxyethanol, dehydroacetic acid and benzoic acid mentioned in the formulation is obtainable from Schülke & Mayr under the name Euxyl^R K702.

5

Example 5

A cream was prepared from the following constituents, which are indicated by their INCI names.

10

INCI

Ceteareth-25	3.0	g
PEG-4-polyglyceryl 2-stearate	2.0	g
Cetearyl alcohol	4.9	g
Petrolatum	10.0	g
Paraffinum perliquidum	3.0	g
Sodium carbomer 400	0.14	g
Lactic acid	0.02	g
Paraffinum perliquidum	2.0	g
Phenoxyethanol, dehydroacetic acid, ben-		
zoic acid	0.4	g
Perfume	0.08	g
4-acetylandrost-4-ene-3,17-dione		
(acetylated formestane)	1.5	g
made up with water to	100	g

10

15

20

. .

14

Example 6-

7868St Øt 67+

A clinical test of the recipe according to Example 1 was carried out. The findings of oversize breasts and medium-grade mastopathy were present in the 25-year-old volunteer.

A fine needle aspirate of the fatty tissue (0.6 mm puncture needle, fixation in absolute ethanol, staining: May-Grünwald-Giemsa) was withdrawn (Fig. 1). Distended fat cells and eccentric cell nuclei as a result of a high oestrogen influx are detected.

The volunteer then applied the cream according to Example 1 twice daily over a period of 3 months. Fig. 2 shows the fatty tissue aspirate after this use. A reduction in volume of the fatty tissue ("shrivelled" fat cells in a regular arrangement) and an increase in connective tissue is detected due to the aromatase inhibition. The results showed a reduction of the tissue at risk by about 50% and a distinct firming of connective tissue and skin.

> בני מבף, בטטט בטינט ששה מרטה פוחכת ממשחם.

4 State .

South officer South in

fi...

Same Same S....

æ as is ing is

ka b Man A

W W W W

20

1.


- Use of a steroidal aromatase inhibitor for the preparation of a medicament formulated for topical application for the prophylaxis and/or treatment of breast cancer, where the medicament contains no antigestagens.
- Use according to Claim 1, characterized in that the me-10 2. dicament contains formestane (4-hydroxyandrost-4-ene-3,17-dione) and/or a pharmacologically active formestane derivative.
- 15 3. Use according to Claim 2, characterized in that the medicament contains 4-0-acetylandrost-4-ene-3,17-dione.
 - Use according to one of Claims 1 to 3, characterized in that the medicament additionally contains substances for promoting skin penetration.
 - Use according to Claim 4, characterized in that the me-5. dicament contains DMSO.
- Use according to one of Claims 1 to 5, characterized in 25 6. that the medicament is formulated as an ointment, cream, gel, emulsion or lotion.
- Use according to Claim 6, characterized in that the ac-7. tive compound content is 0.0001-20% by weight, prefera-30 bly 0.6-10% by weight, further preferably 1-5% by weight.

01/01 % ሕበ<u>ር</u>ቱ ''••

Fig. 1



Fig. 2



NOU 18 '00 18:15 FR MOFO DC

TO 2788#9999815#811 P.86/88

PATENT Docket No.

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled:

DRUG FOR THE PROPHYLAXIS AND/OR TREATMENT OF BREAST CANCER, COMPRISING A STEROIDAL AROMATASE INHIBITOR

the specification of which is attached hereto unless the following box is checked:

- was filed on September 18, 2000 as United States Application Serial No. 09/646,355
- as amended by the Preliminary Amendment filed concurrently with the application on September 18, 2000.

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

WE acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.36.

WE hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United Scales listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority (Mained?
PCT/EP99/01374	EP	03/03/99	因Yes	□No
EP 98104949.7	EP	03/18/98 /	⊠Yes	□No
			□Yes	□No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

dr-143388

1 B

Thing,

Hall after Conf.

firm firm

179

is mak

æ å

j≃ k

g.

Empfangszeit 11. Nov. 0:13

icia nonz nan bi

ij.

100 m

Gall Son

Ųį

Gram

The second

ä

122 12

i me is Ţ,

C]

NOU 18 '00 18:16 FR MOFO DC

TO 2700H999901SR011 P.07/08

Application Serial No.	Filing Date
· · · · · · · · · · ·	

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112. We acknowledge the duty to disclose information which is material to parentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Piling Date	Sterus		
		□ Patented	Pending	□ Abandoned
		□ Patented	DPending	[]Abandoned

We hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Mani Adeli (Reg No. 39,585) Erwin J. Basinski (Reg No. 34,773) Paula A. Borden (Reg No. 42,344) Barry E. Breischneider (Reg No. 28,055) Alan W. Cannon (Reg No. 34,977) Robert K. Corpa (Reg No. 39,933) Niki D. Cox (Reg No. 42.446) E. Victor Donahue (Reg No. 35,492) Seen M. Fitzgerald (Reg No. 42,537) Hector Gallegos (Reg No. 40,614) Charles D. Holland (Reg No. 35,196) Richard D. Jordan (Reg No. 33,519) Ararat Kapouytian (Reg No. 40,044) Antoinene F. Konski (Reg No. 34,202) Susan K. Lehnhardt (Reg No. 33,943) Shmuel Livnar (Reg No. 33,949) Harry J. Macey (Reg No. 32,818) Gladys H. Monroy (Reg No. 32,430) Dahna S. Pasternak (Reg No. 41,411) William C. Revelos (Rog No. 42,101) J. Michael Schiff (Reg No. 40,253). Lee K. Tan (Reg No. 39,447) Thomas G. Wiseman (Reg No. 35,046) Frank Wu (Reg No. 41,386) Paul J. Riley (Reg. No. 38,596 Please direct all communications to:

Sanjay Bagade (Reg No. 42,280) Frank P. Becking (Reg No. 42,309) Sean Brennan (Reg No. 39,917) Nicholas Buffinger (Rog No. 39,124) Mark R. Carter (Reg No. 39.131) Thomas E. Ciotti (Reg No. 21,013) Raj S. Davé (Reg No. 42,465) Stephen C. Durant (Rug No. 31,506) Cheryl L. Franke (Reg No. P-44, 113) Douglas Hodder (Reg No. 41,840) Madeline L Johnston (Reg No. 36,174) Cindy S. Kaplan (Reg No. 40,043) Phanesh B. Koneru (Reg No. 40,053) Jung-Hua Kuo (Reg No. 41,918) Won Liu (Reg. No. 32,822) David C. Lundmark (Reg No. 42,815) Thomas D. Mays (Reg No. 34,524) Kare H. Murashigo (Reg No. 29,959) Catherine M. Polizzi (Reg No. 40,130) Robert Saltzberg (Reg No. 36,910) Debra A. Shetka (Reg No. 33,309) E. Thomas Wheelock (Reg No. 28,825) Karen K. Wong (Reg No. P-44,409) Kevin R. Spivak (Reg. No. 43,148)

2

Docket No.

11 Nov. 0:13 Empiangazeit

16, Nov. 10:4489 TOW SATER THATA

HARZ ADN 'TI

+49 7666 Nr. 74461 S. 7/9 S.07

NOU 19 '88 19:16 FR MOFO DC

TO 2700H99999015H011 P.88/08

Barry E. Breuschneider Marrison & Foerster us 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888

Please direct all telephone calls to Barry E. Bretschneider at (202) 887-1545.

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Residence: Sucheruschen 17,22529 Handway, Germany
Citizenship: Germany Hamburg

Pain Office Address: Submischon 17, 22529 Hambary, Germany

dome: Molarich Williams

Residence: In der Wiehre 13. 7927 St. Feet, Germany DEX

CIUDANAIR GARBANY -

Past Office Address In der Wichre 13, 79271 St. Poter, Germany

Dake

Name: Residence:

Citizenship:

Pars Office Address:

Date

Man the trust them I I

1

ff....

∺

jag k

g1

Name:

Residence:

Cionenthip:

POR Office Address:

Date

Name:

Residence:

Citizanahip:

Post Office Address:

Docket No.

Emplaneszeit

1:, Nov. 0:13

** TOTAL PAGE. 08 **

6/8 'S (bf/ Empfangszeit 16. Nov. 10:44 и этом сатап тыкта

ANA? 'ARM 'b